Activites

• 2003/06/25 Final act published in Official Journal
  • Directive 2003/34
  • OJ L 156 25.06.2003, p. 0014-0016
• 2003/05/26 Final act signed
• 2003/05/26 End of procedure in Parliament
• #2500
• 2003/04/08 Council Meeting
• 2003/03/27 Decision by Parliament, 3rd reading
  • T5-0121/2003 summary

    The European Parliament adopted a resolution approving the text jointly agreed by the Conciliation Committee. (Please refer to the document dated 17/03/03).�

• 2003/03/26 Debate in Parliament
  • Debate in Parliament
• 2003/03/11 Joint text approved by Conciliation Committee co-chairs
  • 3606/2003
• 2003/02/18 Formal meeting of Conciliation Committee
• 2003/01/22 Report tabled for plenary, 3rd reading
  • A5-0064/2003
• #2480
• 2003/01/21 Council Meeting
• 2002/10/10 Debate in Parliament
  • Debate in Parliament
  • T5-0460/2002 summary

    The European Parliament adopted a resolution drafted by Giuseppe NISTICO (EPP-ED, Italy) which slightly amends the Council's common position. A clause is added to one of the recitals, stating that the Commission should submit a proposal to prohibit the use of products containing c/m/r substances, when there is scientific evidence that they are released from these products leading to exposure of the general public.�

• 2002/09/10 Vote in committee, 2nd reading
  • A5-0285/2002
• 2002/06/13 Committee referral announced in Parliament, 2nd reading
• #2431
• 2002/06/03 Council Meeting
  • 08328/1/2002 summary

    The European Parliament adopted 2 amendments, proposing to extend the restrictions to products. The Council has rejected both amendments. The Council cannot agree to an extension of the scope of the application of the Directive without basing it on a scientific evaluation or a risk assessment. According to the current legislative framework, it is for the Member States and the Commission to determine, on the basis of a risk assessment, whether substances and preparations, and products containing them pose a risk to public health or the environment. In this respect, it should be recalled that a very high number of CMR substances exists and that these are contained in an indefinite number of products. A product based approach to CMR substances would thus be impossible to apply in practice. Furthermore, the Council considers that the proposed restrictions on certain CMR substances and preparations containing them provide adequate measures to limit the use of those CMR substances. It has therefore rejected the Parliament's amendments.�

• 2002/02/05 Decision by Parliament, 1st reading/single reading
  • T5-0025/2002 summary

    The European Parliament adopted, without debate, the report by Mr Giuseppe NISTICO (EPP-ED, I). �

• 2002/01/22 Vote in committee, 1st reading/single reading
  • A5-0015/2002
• #2389
• 2001/11/26 Council Meeting
  • 2389
• 2001/05/17 Committee referral announced in Parliament, 1st reading/single reading
• 2001/05/14 Legislative proposal published
  • COM(2001)0256 summary

    PURPOSE : to amend for the 23rd time Council Directive 76/769/EEC relating to restrictions on the marketing and use of certain dangerous substances and preparations (substances classifed as carcinogens, mutagens or substances toxic to reproduction - c/m/r). CONTENT : within the framework for action in the field of public health, the European Parliament and the Council have adopted an action plan to combat cancer (Decision 646/96/EC). Due to the fact that use of chemicals by consumers cannot be controlled, safety can only be ensured by prohibiting use by consumers of c/m/r substances and preparations. Following the adoption of the Directive 94/60/EC the Commission is invited to propose measures governing substances newly classified as c/m/r categories 1 or 2. The aim of the proposal is to preserve the Internal Market and at the same time ensure a high level of protection of health of the consumers. When Member States adopt national provisions restricting the marketing and use of c/m/r substances and preparations there will be obstacles to trade because of different development of national legislation. It is therefore necessary to improve the conditions for the functioning of the Internal Market to the benefit of the protection of the health and safety of consumers. The only course of action available is a proposal for an amendment to Directive 76/69/EEC, the 23rd amendment, providing for harmonised rules on the use of substances and preparations classified as category 1 or 2 c/m/r's. The proposed 23rd amendment establishes uniform rules for the circulation of substances and preparations classified as c/m/r. It also guarantees a high level of protection of health and safety of consumers. The proposed 23rd amendment is the only way to meet these goals. The proposed ban will ensure that the carcinogenic and mutagenic substances and substances toxic to reproduction and preparations are not placed on the market for consumer use either now or in the future. The benefit of the proposal is to protect the health of the consumers.�

  • DG [{'url': 'http://ec.europa.eu/enterprise/', 'title': 'Enterprise and Industry'}],

Documents

• Legislative proposal published: COM(2001)0256
• Debate in Council: 2389
• Committee report tabled for plenary, 1st reading/single reading: A5-0015/2002
• Decision by Parliament, 1st reading/single reading: T5-0025/2002
• Council position published: 08328/1/2002
• Committee recommendation tabled for plenary, 2nd reading: A5-0285/2002
• Debate in Parliament: Debate in Parliament
• Decision by Parliament, 2nd reading: T5-0460/2002
• Report tabled for plenary, 3rd reading: A5-0064/2003
• Joint text approved by Conciliation Committee co-chairs: 3606/2003
• Debate in Parliament: Debate in Parliament
• Decision by Parliament, 3rd reading: T5-0121/2003
• : Directive 2003/34
• : OJ L 156 25.06.2003, p. 0014-0016

History

(these mark the time of scraping, not the official date of the change)